Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

EDAP TMS SA (NASDAQ: EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a 510(k) application for its Ablatherm Fusion device, enabling a more precise method for targeting of diagnosed areas within the prostate.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented: "As recently mentioned, the next generation of Ablatherm devices merge MRI, 3D biopsy maps, and ultrasound images by integrating EDAP's proprietary software and fusion algorithm. This innovative, state of the art option tremendously improves the imaging and targeting capabilities of the Ablatherm while maintaining its unique, proven tissue ablation efficacy."

Marc Oczachowski added: " Ablatherm Fusion is well positioned to perfectly complement our already commercialized range of HIFU devices and offerings. The submitted 510k file is straightforward as it maintains same treatment parameters from the previously approved current generation of Ablatherm devices."

Read more:

EDAP TMS SA (EDAP) Reports 510(k) Application for Ablatherm-Fusion Device - StreetInsider.com